Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

What is TrialNet?

TrialNet is an international network of leading academic institutions, endocrinologists, physicians, scientists and healthcare teams at the forefront of type 1 diabetes (T1D) research. They offer risk screening for relatives of people with T1D and innovative clinical studies testing ways to slow down and prevent disease progression.

Research has shown that family members of people with T1D are at a 15x greater risk of developing T1D than the general population.

The ultimate goal for this program aligns with Breakthrough T1D’s research strategy: identifying preventative and screening measures that will stop the disease before it starts.

How can you help? 

  • TrialNet is focused on finding ways to slow down and prevent the onset of T1D
  • By participating in TrialNet, you can advance scientific research about the development of T1D
  • If you are at high risk for developing T1D, you may be eligible to participate in a prevention trial
  • Previous research in The TrialNet Teplizumab (Anti-CD3) Prevention Study was the first study to demonstrate a drug that can delay T1D diagnosis – which in the most recent analysis showed an average delay of three years in people at high risk. This was an incredible advancement that gets us all one step closer to our goal of a future without T1D.

Step 1: Get Screened

  • Find out if you are at high risk for developing T1D
    • The study looks for markers in your blood that show that you may be on the path to developing T1D
  • You will be given an at-home test-kit that can be done with a finger stick or go to a local lab for a blood draw
  • The kit is available anywhere in Canada at zero cost to participants

Who is eligible?

This screening kit is available to family members of individuals with T1D

Step 2: Find out the results

  • Results take around 4-6 weeks

Step 3: Help researchers better understand the development of T1D

  • If your screening results show that you are at a high risk for developing T1D, you will have the opportunity to be monitored by the TrialNet team for any sign of developing diabetes. You may also be eligible to participate in a TrialNet prevention study, testing ways to slow or stop disease progression.

Results from these trials will help researchers develop preventative treatments and therapies. You can be part of this solution.

https://vimeo.com/338949857

Contact Info

For more information, or to request a screening kit, feel free to contact the TrialNet Team:

1-866-693-1899

Trialnet.diabetes@sickkids.ca

Visit our website for more information: www.trialnet.org